arrow
D

David Sullivan

Royal Prince Alfred Hospital
H指数:64
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Utility of high-sensitivity cardiac troponin I normalized to left ventricular mass in detection of stable coronary artery disease

高灵敏度心肌肌钙蛋白I相对于左心室质量的标准化在稳定型冠状动脉疾病检测中的应用

2026-07-300
OA
Unveiling novel biomarkers for diabetes-related complications through large-scale proteomics analysis: A FIELD sub-study

通过大规模蛋白质组学分析揭示糖尿病相关并发症的新型生物标志物:FIELD子研究

2026-04-190
PRE
Chronic complication risk and benefits of fenofibrate in type 2 diabetes by a PPARα polymorphism (rs6008845, C/T): a FIELD trial substudy

PPARα多态性(rs6008845, C/T)对非诺贝特在2型糖尿病中慢性并发症风险和获益的影响:FIELD试验的亚组研究

2026-02-210
OAAI
Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations (vol 32, pg 287, 2023)
2026-01-010
PRE
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial

Zodasiran,一种靶向ANGPTL3的RNAi疗法,用于治疗纯合子家族性高胆固醇血症患者(GATEWAY):一项开放标签、随机、II期临床试验

2025-12-180
PRE
The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study

血红蛋白结合蛋白水平和表型与2型糖尿病中心血管疾病的关系:一项非诺贝特干预和糖尿病事件降低的子研究

2025-09-011
OAAI
Statin effects on the lipidome: Predicting statin usage and implications for cardiovascular risk prediction

他汀类药物对脂质组的影响:预测他汀类药物使用及其对心血管风险预测的启示

2025-05-010
OAAI
Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudy

2型糖尿病中结合珠蛋白表型和水平与威胁视力的糖尿病视网膜病变的关系:一项非诺贝特干预与糖尿病事件降低(FIELD)的亚研究

2025-04-010
OAAI
Developing a national implementation strategy for enhancing the detection of familial hypercholesterolemia: An Australian experience

制定国家实施策略以增强家族性高胆固醇血症的检测:一项澳大利亚经验

2025-03-200
OAAI